Précis: Metastatic prostate carcinomas exhibit heterogeneous and distinct patterns of dysregulated expression of enzymes involved in androgen metabolism, which can contribute to the maintenance of intratumoral androgens and AR transcriptional activity despite castrate serum levels of testosterone. 
INTRODUCTION
Gonadal androgen depletion and/or blockade have been the standard first-line systemic treatment for advanced prostate cancer (PCa) for the past 7 decades, producing declines in prostate specific antigen (PSA) and tumor regression. Despite peripheral androgen levels in the castrate range, eventual regrowth occurs as a castration-resistant PCa (CRPC) and is invariably lethal (1) . The androgen receptor (AR) signaling axis remains active in most CRPCs, as evidenced by the frequent re-expression of AR target genes such as PSA and TMPRSS2. The AR axis thus represents an important therapeutic target, a concept that has been validated in recent clinical trials of second-line hormonal manipulations with abiraterone acetate, a CYP17 inhibitor that blocks steroid biosynthesis (2-7), and MDV3100 (enzalutamide), a new anti-androgen (5, (8) (9) (10) (11) .
Several mechanisms that allow AR activation despite castrate levels of peripheral testosterone have been reported in CRPC, including the persistence of residual intratumoral androgens at concentrations sufficient to activate AR (12) (13) (14) (15) (16) (17) (18) (19) . Compared to primary prostate tumors or normal prostate tissue, CRPC displays up-regulated expression of several transcripts encoding for enzymes involved in androgen metabolism (18, (20) (21) (22) (23) .
The clinical relevance of the above findings is validated by the activity of the CYP17 inhibitor abiraterone (2) (3) (4) (5) (6) (7) , recently shown to prolong overall survival in chemotherapy-treated CRPC Author Manuscript Published OnlineFirst on September 12, 2012; DOI: 10.1158/0008-5472. CAN-12-1335 AKR1C3) (24) , suggesting maintenance of capacity for in situ steroidogenesis as a potential mechanism of treatment failure. Additional data suggest that intratumor CYP11-dependent pregnenolone/progesterone synthesis can contribute to resistance to abiraterone (25) and strengthen the notion that CRPCs resistant to CYP17 inhibition may remain ligand-dependent and AR-dependent, and, therefore, responsive to therapies that can further suppress de novo intratumoral steroid synthesis (25) . We hypothesized that the delineation of the mechanisms leading to dysregulated expression of androgen metabolism enzymes would provide important insight into possible mechanisms of resistance to abiraterone, and would help identify additional targets in this pathway and facilitate rational design of future drug combinations for clinical trials in CRPC as candidate components of a comprehensive AR axis targeting approach.
Towards that aim, we mined datasets from a recently reported comprehensive integrated oncogenomic analysis of banked tissue samples from primary and metastatic prostate PCas and normal prostate controls (26) in order to define the frequency of alterations in androgen metabolism pathways. We found aberrant expression for several of these steroidogenic enzymes and investigated mechanisms accounting for this phenomenon.
Research. 
MATERIALS AND METHODS

PCa tissue specimens and oncogenomic profiling
The methodology for our integrated analysis of transcriptomes and CNAs in prostate cancer has been reported previously (26) . Briefly, gene expression profiles of 29 normal prostate tissue samples, 131 primary PCas and 19 metastatic (8 non-castrate, 11 castrate) PCas were generated using Affymetrix Human Exon 1.0 ST arrays. Data from 4 primary tumor samples were excluded from analysis due to prior neoadjuvant hormonal or chemotherapy treatment. Expression outliers, defined as transcripts with significant up-or downregulation in that particular specimen compared to the distribution of expression for that transcript in normal prostate samples, were determined as previously (26) (27) . In this nonparametric approach, an empirical distribution function generated from transcript expression in the 29 normal prostate tissues was used to transform expression in the tumor samples, from which outliers were determined with the criteria described in the Benjamini and Hochberg algorithm (28) at an error rate (a) = 0.01 (26) .
Copy-number alterations (CNAs) were assessed with Agilent 244K array comparative genomic hybridization (aCGH) microarrays (described in detail in (26) ).
All patients provided informed consent. Samples were procured and the study was conducted under MSKCC Institutional Review Board (IRB) approval. Clinical and pathologic data were entered and maintained in a prospective prostate cancer database.
Research. The complete data is freely available through a web-based portal (29). The full raw data is available via GEO (accession no. GSE21032).
List of studied transcripts
We studied transcripts for enzymes participating in androgen synthesis and metabolism (Fig. 1A and Suppl. Table 1 ). We also used a previously published AR-dependent transcript signature (30) and applied it to our gene expression data to quantify AR axis signaling output.
In vitro treatment of PCa cells
PCa LNCaP cells (purchased from American Type Culture Collection, Manassas, VA, and passaged for fewer than 6 months) were grown in RPMI-1640 medium supplemented with 10% FBS (Omega Scientific, Tarzana, CA). For androgen deprivation, the cells were incubated in RPMI-1640 medium supplemented with 10% charcoal-stripped FBS (CSS, Omega Scientific) for 48 hrs. R1881 (NEN Life Science Products, Boston, MA) was used at 1 nM. The novel antiandrogen MDV3100 (enzalutamide; Medivation, San Francisco, CA) (8-9) was used at 10 μM. Quantitative RT-PCR analysis for steroidogenic enzyme expression was performed using a
StepOne Plus instrument and Taqman probes (both from Applied Biosystems, Foster City, CA). 
Statistical analysis
The average expression of each transcript of interest was compared between normal prostate tissue, primary PrCa and metastatic PrCa using one-way analysis of variance (ANOVA) and the LSD, Bonferroni and Dunnett C post-hoc tests. Two-sided t-tests were used to compare the number of "pro-androgenic" or "anti-androgenic" transcripts that are differentially expressed in metastastic vs. primary carcinomas. Chi-square tests were used to compare the number of cases of metastastic vs. primary carcinomas that had differential expression of at least one "pro- 
RESULTS
High interpatient variability of dysregulated expression of individual transcripts involved in androgen metabolism in PCa
Expression of our panel of transcripts encoding for enzymes involved in androgen synthesis and metabolism ( Fig. 1A and Suppl. Table 1 For the transcripts that are expected to have a "pro-androgenic" effect (i.e. increase ligand availability and, thus, AR activity: Group A in Suppl. Table 1) , we found that metastatic carcinomas overexpressed, on average, 4.7 transcripts ((range 1-13, SD 2.7), compared to 1.7 transcripts in the primary carcinomas (range 0-11, SD 2.0, 2-sided t-test P=0.00024). All (19/19) metastastic carcinomas overexpressed at least one such transcript, compared to 92/127 for primary carcinomas (Chi-square P<0.01). For the "anti-androgenic" transcripts (i.e. enzymes overall associated with androgen degradation/inactivation and, thus, expected to decrease AR activity: Group B in Suppl. Table 1 ), the metastatic carcinomas under-expressed, on average, 3.5 transcripts (range 0-9, SD 2.2), compared to 2.6 transcripts for the primary carcinomas (range 0-9, SD 2.0, 2-sided t-test P=0.128). Moreover, 18/19 metastatic carcinomas under-expressed at least one such transcript, compared to 102/127 for primary carcinomas (Chi-square P=0.125).
Thus, consistent with the data in Figure 1B , metastatic tissues exhibited significantly more variable expression patterns than primary carcinoma or normal prostate tissue.
Association of expression of transcripts involved in androgen metabolism with AR transcriptional output
We investigated whether the variability in expression of these steroid-related transcripts leads to enhanced AR signaling output. We calculated a "composite steroid enzyme expression" as the sum of the "pro-androgenic" transcripts (that overall are associated with steroid synthesis and increased AR activity) minus the sum of the "anti-androgenic" transcripts (that overall are involved in androgen degradation/inactivation and, thus, expected to decrease AR activity), and 
Gene copy-number alterations appear not to be the cause of dysregulated expression of transcripts involved in androgen metabolism in PCa
We integrated the copy-number alterations (CNAs) identified in (26) Thus, for most of these genes, transcriptional regulation, rather than altered gene copy number, is the likely cause of dysregulated expression.
Patterns of coordinated expression of transcripts involved in androgen metabolism in PCas suggest distinct regulatory mechanisms
As our results suggested that the dysregulation of androgen-related transcripts in PCas occurs at the transcriptional level, we assessed for similarities in the pattern of their expression that might indicate the existence of common regulatory mechanisms. Using linear correlation analysis of the log2-based mRNA levels in primary and metastatic carcinomas, we identified 4 distinct groups of transcripts with highly co-regulated patterns of expression (Suppl. 
The enzymes of the AKR1C family are negatively regulated by androgen
We next investigated the regulation of the Group 2 transcripts, i.e. the AKR1C family enzyme transcripts, because AKR1C3 plays a crucial role in conversion of DHEA and androstenedione to testosterone. We mined our transcriptome data (from primary and metastatic tumors) for transcripts highly co-regulated with AKR1C3. Not surprisingly, we found the other family members, AKR1C1, AKR1C2 and AKR1C4, to be co-regulated (Suppl. Table 5 ). Transcripts highly negatively associated with AKR1C3 were KLK3, ACPP, ABCC4, KLK2 and other ARdriven transcripts (Suppl. Table 5 ). These findings suggested that high AKR1C family enzyme expression is inversely associated with AR activity. This was confirmed in our transcriptome data from metastatic specimens, where the AR transcriptional output (quantified using an ARdependent gene signature previously derived by treating the LNCaP prostate cancer cell line with androgen for 24 hrs (30)), was inversely associated with expression of each individual AKR1C family enzyme (Fig. 6A) .
Research. We tested this hypothesis in vitro by measuring AKR1C3 transcript expression in LNCaP cells deprived of androgen. Incubation in medium supplemented with steroid-depleted serum resulted in potent upregulation of AKR1C3 (Fig. 6B) . This effect was reversed by addition of the synthetic androgen R1881, confirming the negative impact of androgen on AKR1C family enzyme expression (Fig. 6B) . Furthermore, the novel anti-androgen enzalutamide stimulated AKR1C3 expression (Fig. 6B) , confirming that both AR antagonism and androgen deprivation can upregulate AKR1C3.
Analysis of human CTCs from CRPC patients for expression of AR, PSA and steroidogenic enzymes
Multiplex qRT-PCR analysis for AKR1C3, SRD5A1, CYP17A1, AR, and KLK3 (PSA) transcripts revealed positivity in CTCs purified from the peripheral blood of CRPC patients (Fig. 7) . This provides proof-of-principle that these steroidogenic enzymes can be detected in CTCs, and further confirms that they are expressed by the EpCaM(+) epithelial component of the tumor. 
DISCUSSION
Suppression of gonadal androgen synthesis does not achieve complete ablation of androgen signaling in the prostate microenvironment. Even when circulating testosterone is confirmed to be at castrate levels, intratumoral androgens persist at levels sufficient to activate AR (12) (13) (14) (15) (16) (17) .
CRPC can locally convert adrenal precursors to more active androgens (testosterone and DHT) (31-32). Moreover, de novo steroidogenesis in CRPC, using cholesterol as a precursor, has been supported by some (18, 22, 33) , but not all studies (21) . In the present study, we investigated the mechanism(s) leading to aberrant expression of enzymes involved in steroid metabolism in CRPC. Using data from an integrated oncogenomic analysis of primary and metastatic specimens (26), we documented that metastatic PCas express higher average transcript levels for AR and several steroidogenic enzymes, including SRD5A1, SRD5A3, and AKR1C3, while expression of SRD5A2, CYP3A4, CYP3A5 and CYP3A7 is decreased, compared to normal prostate tissue or primary prostate carcinoma. Collectively, these data demonstrate that CRPC cells have increased expression of AR and steroidogenic enzymes, and decreased expression of enzymes that can inactivate DHT (CYP3A4, CYP3A5 or CYP3A7), a state that is predicted to increase in situ androgen levels and enhance AR activation. This was supported by the finding of positive correlation between the composite enzyme expression and the AR transcriptional signaling output signature (a measure of AR activation) in our samples. The aberrant expression patterns of androgen axis transcripts were only rarely associated with respective CNAs in our cohort, suggesting that this dysregulation occurs mainly at the mRNA level. Analysis of these expression patterns identified distinct groups with highly co-regulated expression. One group of transcripts, comprising aldo-keto reductase family 1 (AKR1C1 through 4), was found to be inversely correlated to AR transcriptional activity, as reflected by an ARdependent gene signature (30) . This suggested that the expression of the AKR1Cs is suppressed by androgen. We confirmed that both androgen deprivation and an AR antagonist induce AKR1C3 expression. The AKR1C1-4 genes are located on chromosome 10p15 in tandem, sharing > 86% amino acid sequence identity (37) . Our findings suggest that androgen deprivation triggers a feedback loop that enhances the ability of PCa cells to metabolize adrenal precursors into testosterone and DHT, thus sustaining tissue androgen levels. Evidence for such a feedback loop was recently reported in CRPC patients, where treatment with the AR antagonist enzalutamide resulted in increased bone marrow testosterone levels (41) . Moreover, abirateroneresistant PCa xenografts overexpress several steroidogenic enzymes, including AKR1C3 (24).
This proposed adaptation/survival mechanism is also supported by the finding that, after gonadal androgen suppressive therapy, intraprostatic androgen levels persist at ~25% of baseline (while serum androgen levels decrease to ~7.5% of baseline) and are no longer correlated with the CAN-12-1335 serum level of testosterone, but with serum levels of the adrenal precursors DHEA and DHEA-S (12) (13) 42) . This suboptimal suppression of intratumoral androgens may allow for the survival of cancer cells that will eventually lead to CRPC. Indeed, the rate of pathologic complete response in prostatectomy specimens removed after 3 to 8 months of neoadjuvant androgen deprivation therapy is < 3% (43) . Collectively, these findings support our hypothesis that the almost universal persistence of PCa cells after gonadal androgen suppression, and the eventual emergence of CRPC, are facilitated by adaptive cellular changes that occur very early after initiation of gonadal suppression and allow PCa cells to maintain adequate intratumoral androgen levels and survive despite peripheral castrate androgen levels. A more comprehensive AR axis targeting at multiple levels (androgen synthesis, metabolism and action) and at all relevant sites (gonadal, adrenal, intratumoral) simultaneously at the time of initiation of endocrine therapy, aiming at maximal frontline inhibition of the AR axis, is warranted, instead of the current treatment paradigm of sequentially adding agents at the time of disease progression (44).
Clinically, our hypothesis can be tested in trials incorporating abiraterone and/or enzalutamide at the time of initiation of GnRH analog therapy in the neoadjuvant or metastatic setting.
Preliminary observations support the promise of this approach (45) . Furthermore, AKR1C3 inhibitors (37-40) would also be interesting choices to be tested concurrently with GnRH analogs. A recently reported bifunctional inhibitor of both AKR1C3 and AR represents an intriguing paradigm (46) .
An obvious limitation of our study is that, due to the retrospective nature of the analysis, direct measurement of androgen levels in these tissues could not be performed. Consequently, the correlation between mRNA levels and enzymatic activity cannot be confirmed in this study. A. Cholesterol, the precursor of all steroidogenesis, is converted to DHT via several enzymatic steps: In the Δ5 pathway (named after the presence of a double carbon bond in the C5 position of the A steroid ring; steroids highlighted in green) and the Δ4 pathway (steroids highlighted in light red), testosterone is synthesized and then reduced by 5α-reductases to DHT, that has a ~5-10-fold higher affinity for AR. Androgen precursors can also be reduced before testosterone synthesis, generating an alternate pathway ("backdoor pathway", steroids highlighted in light blue) that bypasses testosterone and leads to DHT. This pathway has been proposed to be active in prostate tissue, in particular prostate cancer (17) . Recently, it was demonstrated that the dominant route of DHT synthesis in CRPC bypasses testosterone (23) , and instead requires 5α- 
